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ABSTRACT
Diarrhoea caused by enterotoxigenic Escherichia
coli (ETEC) requires adhesion of microorganisms
to enterocytes. Hence, a promising approach to
immunoprophylaxis is to elicit antibodies against
colonisation factor antigens (CFAs). Genes encod-
ing the most prevalent ETEC-speciﬁc surface
antigens were cloned into Vibrio cholerae and
Salmonella vaccine strains. Expression of surface
antigens was assessed by electron-microscopy.
Whereas negative staining was effective in reveal-
ing CFA ⁄ I and CS3, but not CS6, immunolabelling
allowed identiﬁcation of all surface antigens
examined. The V. cholerae vaccine strain CVD103
did not express ETEC-speciﬁc colonisation
factors, whereas CVD103-HgR expressed CS3
only. However, expression of both CFA ⁄ I and
CS3 was demonstrated in Salmonella Ty21a.
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Enterotoxigenic Escherichia coli (ETEC) is a major
cause of diarrhoea worldwide [1]. Despite exten-
sive research, no licensed vaccine for humans is
available to date. The pathogenesis of ETEC
diarrhoea involves two crucial steps that concur-
rently provide two possible targets for vaccine
development: the attachment of the bacteria to the
mucosa of the small intestine via speciﬁc coloni-
sation factors, and the subsequent secretion of at
least one of two enterotoxins [2].
Attachment of microorganisms to enterocytes is
mediated by adhesins termed colonisation factor
antigens (CFAs) or pili [3], and 22 different ETEC
surface antigens have been reported [4]; however,
70% of isolates associated with diarrhoea in
humans express either CFA ⁄ I, CFA ⁄ II or CFA ⁄ IV
[5] or a combination of these [2]. Epidemiological
studies have shown that the expression of these
CFAs varies according to geographical location
and time. Hence, surface antigens occurring with
the highest frequency in the target population
should be included in a future vaccine against
ETEC diarrhoea [6]. A possible approach to a
vaccine might aim at generating a live recombi-
nant polyvalent vaccine strain that simulta-
neously expresses the most relevant ETEC pili.
As a ﬁrst step towards the creation of such a
polyvalent vaccine strain, the present study
describes the expression and morphology of
ETEC-speciﬁc CFA ⁄ I, CS3 and CS6 in recombi-
nant monovalent Vibrio cholerae CVD103,
CVD103-HgR and Salmonella Ty21a vaccine
strains.
The following strains were used: E. coli strains
DH10B (K12 laboratory strain), H10407, DS198-1,
B7A and E34420A (wild-type strains); V. cholerae
CVD103 and CVD103-HgR; and Salmonella Typhi
Ty21a. The construction of V. cholerae recombi-
nant strains has been reported previously [7].
Salmonella Typhi Ty21a recombinant strains
were obtained by electroporation of plasmids
pSSVI215-cfaI ⁄ S, pSSVI215-CS3, and pSSVI215-
CS6. The stability of plasmids was analysed by
growing the cultures in exponential phase for ten
generations in the absence of antibiotics. The
persistence of plasmids was then conﬁrmed in
single colonies by growth on solid medium
containing the corresponding antibiotics and
by plasmid puriﬁcation. Bacterial strains were
cultured and processed as described previously
[8]. ETEC wild-type strains expressing corre-
sponding surface antigens were used as positive
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controls. Control reactions for immunogold label-
ling included omission of primary antibodies and
use of inappropriate antibodies as substitutes for
pertinent primary antibodies. Expression of
CFA ⁄ I, CS3 and CS6 pili in recombinant
monovalent vaccine strains was matched with
the expression of corresponding surface antigens
in ETEC wild-type strains. Binding patterns of
monoclonal antibodies in western blots are shown
in Fig. 1. The polyclonal antibodies used dis-
played extensive non-speciﬁc binding patterns in
ETEC wild-type H10407 and E. coli K12 strains
(results not shown). The results of analysis by
electron-microscopy using negative staining and
immunogold labelling are shown in Fig. 2.
The present study was undertaken to validate
the expression of ETEC-speciﬁc surface antigens
by three carrier strains with respect to their
potential use as vaccines. In view of the current
epidemiology of ETEC, a vaccine comprising
CFA ⁄ I, CS3 and CS6 ﬁmbriae would provide
protection against 50–70% of all ETEC infections,
depending on variations in the regional preva-
lence of these adhesion factors. Inclusion of
further, non-ﬁmbrial, antigens might increase
coverage even further.
The use of live carrier bacteria is widely recog-
nised as a valid vaccine strategy against intestinal
pathogens. One of the main drawbacks relates to
vaccine safety. However, the use of marketed live
vaccines as carriers of foreign antigens has pro-
vided evidence of clear medical and regulatory
advantages. In such a vaccine, stabilisation of
antigens, either by integrating the corresponding
genes into the carrier’s chromosome or by using a
so-called lethal balanced system, is compulsory. In
the present proof-of-concept study, molecular
methods were used to ensure that plasmids
carrying the genes for the relevant antigens were
stable and that the genes were expressed. Beyond
this, proper synthesis and location of the expected
proteins must be established in potential vaccine
strains. The present study used transmission
electron-microscopy, in combination with nega-
(a) (c) (e)
(f)(d)(b)
Fig. 1. Western blot assays showing reactivity of mouse monoclonal anti-CFA ⁄ I, anti-CS3 and anti-CS6 antibodies with
laboratory and wild-type strains, with native and recombinant host strains, and with puriﬁed antigen.
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tive staining and immunogold labelling, to assess
the expression of cloned genes and the physical
presence of the corresponding antigens in recom-
binant host strains in comparison with wild-type
strains. Substantial cross-reactivity was observed
in western blot analysis with all polyclonal anti-
bodies employed, but these antibodies were valu-
able in monitoring the expression of pilin in
recombinant vaccine strains, as the prominent
cross-reactivity seen in E. coli was virtually absent
in most host strains.
Negative staining was a useful tool for visualis-
ing CFA ⁄ I and CS3 pili. However, the morphology
varied, and the ﬁmbriae expressed in recombinant
strains seemed to be more frail and were lost more
easily during sample handling. As themorphology
of pili is dependent on strain properties as well as
handling procedures, negative staining is insufﬁ-
cient to characterise these surface structures. In
contrast, immunogold labelling with speciﬁc anti-
CFA ⁄ I antibodies provided unequivocal evidence
of CFA ⁄ I and CS3 expression.
CS3 pili were demonstrated by negative stain-
ing, but theirmorphology varied and depended on
the host in which they were expressed. Immuno-
gold labelling conﬁrmed the presence of a contin-
uous ﬁmbrial layer in ETEC wild-type strains. In
recombinant V. cholerae CVD103-HgR-CS3 and
Salmonella-CS3, CS3 pili appeared as cluster-like
structures. These observations are consistent with
previous ﬁndings of focal CS3 pili expression in
recombinant CVD103-HgR strains [9].
To date, it has not been possible to demonstrate
CS6 pili morphologically, even in ETEC wild-type
strains [7,9–11]. Interestingly, the only labelling
observed with monoclonal anti-CS6 antibodies
was limited to the immediate vicinity of damaged
bacterial wall areas in wild-type ETEC CS6.
Considering the preferential labelling of CS6 pilin
seen in immunoblots, monoclonal anti-CS6 anti-
bodies are likely to identify intracellular antigen
becoming accessible following cell leakage in
electron-microscopy. CS6 surface antigens are
known to be synthesised via the chaperone-usher
pathway [12], with the single CS6 pilins being
assembled in the periplasmic space. Proper for-
mation depends on the presence of appropriate
machinery. The seemingly contradictory ﬁnding
that CS6 can be demonstrated on recombinant
V. cholerae strains by western blots, but fails to
appear at the cell surface in immunogold label-
ling, may reﬂect the accumulation of pilin
subunits in the periplasmic space because of the
absence of required chaperones and ushers. In
contrast, the presence of CS6 pilin was revealed
by western blot analysis because of fractionation
of bacteria, while immunogold labelling failed to
reveal the antigen because of its seclusion in the
periplasmic space.
In summary, plasmid-encoded expression of
genes encoding surface antigens resulted in ade-
quate surface expression of CFA ⁄ I pili in recom-
binant Salmonella-CFA ⁄ I strains, and CS3 pili
were formed in V. cholerae CVD103-HgR-CS3
and Salmonella-CS3 strains. Of the three vaccine
strains examined, Salmonella Ty21a was the most
promising candidate carrier for expressing ETEC-
speciﬁc surface antigens. The use of Salmonella
Typhi strains as vectors would have the added
advantage of including another important enteric
pathogen in a highly speciﬁc polyvalent live
attenuated vaccine.
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Fig. 2. Analysis by electron-microscopy using negative staining and immunogold labelling following addition of
monoclonal anti-CFA ⁄ I antibodies. (a) Labelling of the wild-type strain H10407. Absence of labelling of the native host
strains (b) CVD103 and (c) SalmonellaTy21a substantiates the suitability of the detection system. (d) Recombinantmonovalent
strain CVD103-CFA ⁄ I did not exhibit any immunogold labelling, but (e) CFA ⁄ I pili were visualised at the surface of
Salmonella-CFA ⁄ I by negative staining and immunogold labelling. (f–j) Corresponding strains after labelling with anti-CS3
antibodies: (f) labelling of wild-type strain DS198-1 and the absence of signal on the native host strains (g) CVD103-HgR and
(h) Salmonella Ty21a corroborates the reliability of the detection system. CS3 pili were visualised at the surface of the
monovalent recombinant strains (i) CVD-HgR-CS3 and (j) Salmonella-CS3. (k–m) Control experiments: apart from a few
occasional gold particles, no signal was observed when wild-type strains were labelled with (k) mouse monoclonal anti-
osteoprotegerin or (l, m) mouse monoclonal anti-collagen IV as inappropriate primary antibodies. Scale bar = 0.5 lm.
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ABSTRACT
A major IgG-speciﬁc immunodominant VP1
linear epitope of enterovirus 71 (EV71) strain 41
(5865 ⁄ SIN ⁄ 00009), deﬁned by the core sequence
LEGTTNPNG, was identiﬁed by Pepscan analy-
sis. Oligonucleotides corresponding to the amino-
acid sequence of synthetic peptide SP32 were
cloned and over-expressed in Escherichia coli as
a recombinant glutathione-S-transferase (GST)–
SP32 fusion protein. In ELISAs, this protein did
not react with human anti-EV71 IgG antibodies,
but there was signiﬁcant immunoreactivity
according to western blot analysis. The amino-
acid sequence of SP32 was highly speciﬁc for
detecting EV71 strains in western blot analysis,
and showed no immunoreactivity with monoclo-
nal antibodies raised against other enteroviruses,
e.g., CA9 and Echo 6.
Keywords Detection, enterovirus 71, immunodomi-
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